1. Allergan buys back $2B in stock same day CFO announces retirement
Allergan’s board of directors authorized a $2 billion buyback of the drugmaker’s stock.
2. MD Anderson, Pfizer to collaborate on immunotherapy research
The University of Texas MD Anderson Cancer Center in Houston launched a clinical collaboration with Pfizer to study the use of immuno-oncology drugs to treat various solid tumors and blood cancers.
3. Hurricane Maria stalls shipments of Baxter’s IV products to US hospitals: 4 things to know
Baxter International notified customers of shipment delays for two drugs — dextrose and sodium chloride — following Hurricane Maria.
4. AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
AmerisourceBergen pleaded guilty to a federal misdemeanor charge for selling prefilled syringes of oncology drugs packaged in a facility not registered with the Food and Drug Administration.
5. Amgen to launch Humira biosimilar in 2023 following Abbvie settlement
Amgen settled a patent lawsuit with Abbvie over its biosimilar version of Abbvie’s best-selling arthritis drug Humira.
More articles on supply chain:
US Army delivers 3-day fuel supply to Puerto Rican children’s hospital
Why pharmaceutical products in the US don’t include braille labeling
Rite Aid names former Walgreens executive as president, COO
